Task Forces
Submitted by Anonymous (not verified) on 17 November 2025 - 10:50
Task Forces
Severe cutaneous adverse reactions - standard template wording for product information
Submitted by Anonymous (not verified) on 17 November 2025 - 9:53
Severe cutaneous adverse reactions - standard template wording for product information
EMEA-002554-PIP02-19
Submitted by Anonymous (not verified) on 14 November 2025 - 15:46
EMEA-002554-PIP02-19
EMEA-003521-PIP01-23
Submitted by Anonymous (not verified) on 14 November 2025 - 15:45
EMEA-003521-PIP01-23
Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 12, Status: Authorised
Submitted by Anonymous (not verified) on 14 November 2025 - 15:30
Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 20, Status: Authorised
Submitted by Anonymous (not verified) on 14 November 2025 - 14:58
Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 20, Status: Authorised
Incident management plan
Submitted by Anonymous (not verified) on 14 November 2025 - 14:45
Incident management plan
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 14 November 2025 - 14:36
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 14 November 2025 - 14:26
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised
PMS Product user interface (PUI) Training: Product data submission & bulk edit made easy, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2025, 10:00 (CEST) to 6 October 2025, 12:00 (CEST)
Submitted by Anonymous (not verified) on 14 November 2025 - 13:45
PMS Product user interface (PUI) Training: Product data submission & bulk edit made easy, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2025, 10:00 (CEST) to 6 October 2025, 12:00 (CEST)